The whole concept that big PBMs control formularies is INSANE. In a world of biosimilars and generics, they will prevent a Humira biosimilar like Yusimry, which is $594 per month from being available so they can offer a biosimilar that pays them a huge rebate. Costing yr company/premiums more
December 12, 2024 at 3:06 PM
The whole concept that big PBMs control formularies is INSANE. In a world of biosimilars and generics, they will prevent a Humira biosimilar like Yusimry, which is $594 per month from being available so they can offer a biosimilar that pays them a huge rebate. Costing yr company/premiums more
Aetna, last year: so we no longer cover Humira because there's a biosimilar, so you have to take that instead
Aetna, now: so we no longer cover the biosimilar because the manufacturer is no longer a preferred drug maker, blame them, have you considered prednisone?
Aetna, now: so we no longer cover the biosimilar because the manufacturer is no longer a preferred drug maker, blame them, have you considered prednisone?
June 25, 2025 at 5:31 PM
Aetna, last year: so we no longer cover Humira because there's a biosimilar, so you have to take that instead
Aetna, now: so we no longer cover the biosimilar because the manufacturer is no longer a preferred drug maker, blame them, have you considered prednisone?
Aetna, now: so we no longer cover the biosimilar because the manufacturer is no longer a preferred drug maker, blame them, have you considered prednisone?
🚨 Huge announcement today at costplusdrugs.com!
Starjemza™ (ustekinumab-hmny), a biosimilar to Stelara®, is now available in two strengths for $360 without any insurance required!
🆕 www.costplusdrugs.com/medications/...
Starjemza™ (ustekinumab-hmny), a biosimilar to Stelara®, is now available in two strengths for $360 without any insurance required!
🆕 www.costplusdrugs.com/medications/...
November 6, 2025 at 6:31 PM
🚨 Huge announcement today at costplusdrugs.com!
Starjemza™ (ustekinumab-hmny), a biosimilar to Stelara®, is now available in two strengths for $360 without any insurance required!
🆕 www.costplusdrugs.com/medications/...
Starjemza™ (ustekinumab-hmny), a biosimilar to Stelara®, is now available in two strengths for $360 without any insurance required!
🆕 www.costplusdrugs.com/medications/...
🆕 Another Humira® biosimilar is now available at costplusdrugs.com!
Adalimumab-fkjp has been added to our growing lineup of biologic medications. Biosimilars help expand treatment options, and every addition to our platform is another step toward clearer, more straightforward pricing.
Adalimumab-fkjp has been added to our growing lineup of biologic medications. Biosimilars help expand treatment options, and every addition to our platform is another step toward clearer, more straightforward pricing.
March 4, 2026 at 5:33 PM
🆕 Another Humira® biosimilar is now available at costplusdrugs.com!
Adalimumab-fkjp has been added to our growing lineup of biologic medications. Biosimilars help expand treatment options, and every addition to our platform is another step toward clearer, more straightforward pricing.
Adalimumab-fkjp has been added to our growing lineup of biologic medications. Biosimilars help expand treatment options, and every addition to our platform is another step toward clearer, more straightforward pricing.
therapies the health service has secured, financially enabled by making greater use of low-cost generic and biosimilar medicines. The therapy is being manufactured in the UK, at a site near Edinburgh.
February 1, 2025 at 6:07 PM
therapies the health service has secured, financially enabled by making greater use of low-cost generic and biosimilar medicines. The therapy is being manufactured in the UK, at a site near Edinburgh.
If you enjoy dramatic mad scientist Daniil and the intensity of Changeling Route Burakhovsky, please read Biosimilar by peachygreen
#Pathologic
#морутопия
#Pathologic
#морутопия
November 8, 2024 at 11:13 PM
If you enjoy dramatic mad scientist Daniil and the intensity of Changeling Route Burakhovsky, please read Biosimilar by peachygreen
#Pathologic
#морутопия
#Pathologic
#морутопия
Looking for a Stelara biosimilar? We have it!
Starjemza is available now on costplusdrugs.com.
Available strengths:
💉 45mg/0.5mL Prefilled Syringe | $360
💉 90mg/mL Prefilled Syringe | $360
➡️ www.costplusdrugs.com/medications/...
Create your account and get started today: costplusdrugs.com
Starjemza is available now on costplusdrugs.com.
Available strengths:
💉 45mg/0.5mL Prefilled Syringe | $360
💉 90mg/mL Prefilled Syringe | $360
➡️ www.costplusdrugs.com/medications/...
Create your account and get started today: costplusdrugs.com
July 13, 2026 at 4:14 PM
Looking for a Stelara biosimilar? We have it!
Starjemza is available now on costplusdrugs.com.
Available strengths:
💉 45mg/0.5mL Prefilled Syringe | $360
💉 90mg/mL Prefilled Syringe | $360
➡️ www.costplusdrugs.com/medications/...
Create your account and get started today: costplusdrugs.com
Starjemza is available now on costplusdrugs.com.
Available strengths:
💉 45mg/0.5mL Prefilled Syringe | $360
💉 90mg/mL Prefilled Syringe | $360
➡️ www.costplusdrugs.com/medications/...
Create your account and get started today: costplusdrugs.com
I'm proud to have joined this letter in support of the ETHIC Act, which would help prevent pharmaceutical abuse of double patenting in litigation
www.citizen.org/article/grou...
www.citizen.org/article/grou...
Groups and Experts Letter: Support the ETHIC Act - Public Citizen
Letter from organizations and experts supporting the ETHIC Act. The ETHIC Act would combat pharmaceutical patent thicketing used to thwart generic and biosimilar competitors.
www.citizen.org
April 27, 2026 at 1:27 AM
I'm proud to have joined this letter in support of the ETHIC Act, which would help prevent pharmaceutical abuse of double patenting in litigation
www.citizen.org/article/grou...
www.citizen.org/article/grou...
FDA aims to speed biosimilar approvals to increase competition, but experts warn drug prices may not drop quickly.
Why are biologic drugs expensive? Will Trump’s plans make them cheaper?
FDA aims to speed biosimilar approvals to increase competition, but experts warn drug prices may not drop quickly.
bit.ly
November 16, 2025 at 1:00 PM
FDA aims to speed biosimilar approvals to increase competition, but experts warn drug prices may not drop quickly.
NCCN guidelines identify the molecule not an explicit brand or generic, so yes the option can presented particularly when a generic/biosimilar is first launched
September 28, 2026 at 12:58 AM
NCCN guidelines identify the molecule not an explicit brand or generic, so yes the option can presented particularly when a generic/biosimilar is first launched
Trump's Prescription Plan
💊Targeted Drugs: The policy primarily targets brand-name, single-source drugs (those without generic or biosimilar competition).
💊Encourages manufacturers to sell directly to patients through platforms like TrumpRx.gov
#Pinks
💊Targeted Drugs: The policy primarily targets brand-name, single-source drugs (those without generic or biosimilar competition).
💊Encourages manufacturers to sell directly to patients through platforms like TrumpRx.gov
#Pinks
November 29, 2025 at 3:49 PM
Trump's Prescription Plan
💊Targeted Drugs: The policy primarily targets brand-name, single-source drugs (those without generic or biosimilar competition).
💊Encourages manufacturers to sell directly to patients through platforms like TrumpRx.gov
#Pinks
💊Targeted Drugs: The policy primarily targets brand-name, single-source drugs (those without generic or biosimilar competition).
💊Encourages manufacturers to sell directly to patients through platforms like TrumpRx.gov
#Pinks
Erythropoietin and Biosimilar Market Forecasting Growth 2035 | WiseGuyReports www.wiseguyreports.com/reports/epog...
Erythropoietin and Biosimilar Market Forecasting Growth 2035
The Erythropoietin and Biosimilar Market is expected to grow from 34.8 USD Billion in 2025 to 45.2 USD Billion by 2035. The Erythropoietin and Biosimilar Market CAGR (growth rate) is expected to be ar...
www.wiseguyreports.com
September 28, 2026 at 5:24 AM
Erythropoietin and Biosimilar Market Forecasting Growth 2035 | WiseGuyReports www.wiseguyreports.com/reports/epog...
I like how when Aetna complains about my biologic the price ends up being not just ridiculous, but ridiculous TO THE PENNY.
My biologic per dose is $3,176.72. (Yes it's the biosimilar.) My question is...what's with the $6.72?
$3170 isn't expensive enough?
My biologic per dose is $3,176.72. (Yes it's the biosimilar.) My question is...what's with the $6.72?
$3170 isn't expensive enough?
November 19, 2025 at 9:16 PM
I like how when Aetna complains about my biologic the price ends up being not just ridiculous, but ridiculous TO THE PENNY.
My biologic per dose is $3,176.72. (Yes it's the biosimilar.) My question is...what's with the $6.72?
$3170 isn't expensive enough?
My biologic per dose is $3,176.72. (Yes it's the biosimilar.) My question is...what's with the $6.72?
$3170 isn't expensive enough?
Bristol Myers sues Amgen over proposed Opdivo biosimilar reut.rs/4xrSxww
Bristol Myers sues Amgen over proposed Opdivo biosimilar
Bristol Myers Squibb and Ono Pharmaceutical have sued Amgen in Delaware federal court, seeking to block Amgen's proposed U.S. biosimilar of their blockbuster cancer immunotherapy drug Opdivo.
reut.rs
September 15, 2026 at 6:15 PM
Bristol Myers sues Amgen over proposed Opdivo biosimilar reut.rs/4xrSxww
Seriously. We need more companies working in the biosimilar space to drive down costs.
January 5, 2025 at 1:55 PM
Seriously. We need more companies working in the biosimilar space to drive down costs.
More biosimilars mean more access. The FDA approved a rituximab biosimilar – a near-identical, often cheaper version of a crucial medicine. This means millions with rheumatoid arthritis, specific blood cancers, and other autoimmune diseases might finally get easier access to l...
Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
The U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar, developed by Dr. Reddy's Laboratories and to be commercialized by Fresenius Kabi. This approval provides an additional
www.fresenius.com
August 3, 2026 at 8:03 AM
More biosimilars mean more access. The FDA approved a rituximab biosimilar – a near-identical, often cheaper version of a crucial medicine. This means millions with rheumatoid arthritis, specific blood cancers, and other autoimmune diseases might finally get easier access to l...
An able bodied person is never ever going to understand the difficulty of leading a meeting on health technology assessments and biosimilar switching policies while your blood sugar crashes down to levels that would make a non-diabetic faint.
March 13, 2025 at 2:16 PM
An able bodied person is never ever going to understand the difficulty of leading a meeting on health technology assessments and biosimilar switching policies while your blood sugar crashes down to levels that would make a non-diabetic faint.
We just published a reflection paper on streamlining biosimilar approval to increase patient access while maintaining safety. This could potentially reduce clinical trial needs & ensure Europe remains a competitive market for biosimilars.
📣 Submit feedback by 30 Sept 2025
🔗https://europa.eu/!GVX6tp
📣 Submit feedback by 30 Sept 2025
🔗https://europa.eu/!GVX6tp
April 1, 2025 at 1:40 PM
We just published a reflection paper on streamlining biosimilar approval to increase patient access while maintaining safety. This could potentially reduce clinical trial needs & ensure Europe remains a competitive market for biosimilars.
📣 Submit feedback by 30 Sept 2025
🔗https://europa.eu/!GVX6tp
📣 Submit feedback by 30 Sept 2025
🔗https://europa.eu/!GVX6tp
Generic kesimpta is coming to Europe. Alvotech intends to develop a biosimilar formulation. multiplesclerosisnewstoday.com/news-posts/2...
Partners to commercialize Kesimpta biosimilar MS drug in Europe
Alvotech is expanding its partnership with Advanz Pharma to commercialize new products in Europe, including a Kesimpta biosimilar drug for MS.
multiplesclerosisnewstoday.com
June 3, 2025 at 8:18 PM
Generic kesimpta is coming to Europe. Alvotech intends to develop a biosimilar formulation. multiplesclerosisnewstoday.com/news-posts/2...
Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech reut.rs/4wq0K3z
Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech
Swiss generic drugmaker Sandoz will pay up to $77 million upfront to Shanghai Henlius Biotech for rights to three biosimilar drugs to treat cholesterol, lupus and colorectal cancer, the Chinese drugmaker said on Monday.
reut.rs
August 17, 2026 at 3:40 AM
Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech reut.rs/4wq0K3z
China's Jiuyuan Genetic seeks approval for Wegovy biosimilar reut.rs/46oBelh
China's Jiuyuan Genetic seeks approval for Wegovy biosimilar
Jiuyuan Genetic Biopharmaceutical has applied for approval to sell its experimental biosimilar version of Novo Nordisk's NOVOb.CO
blockbuster weight-loss drug Wegovy in China, the Chinese drugmaker said Wednesday.
reut.rs
February 26, 2026 at 9:25 AM
China's Jiuyuan Genetic seeks approval for Wegovy biosimilar reut.rs/46oBelh
New @jama.com commentary by @rachelsachs.bsky.social @dusetzinas.bsky.social &myself on biosimilar drug competition and price declines.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Biosimilar Competition in Oncology—Beyond Insurer Pressure
The high price of drugs continues to be the focus of policy discussions, with attention often drawn to the importance of promoting price competition through the use of generic and biosimilar versions ...
jamanetwork.com
March 11, 2026 at 6:44 PM
New @jama.com commentary by @rachelsachs.bsky.social @dusetzinas.bsky.social &myself on biosimilar drug competition and price declines.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...